Prediction of clinical outcome in glioblastoma using a biologically relevant nine‐microRNA signature

Hayes, Josie; Thygesen, Helene; Tumilson, Charlotte; Droop, Alastair P.; Boissinot, Marjorie; Hughes, Tom; Westhead, David R.; Alder, Jane; Shaw, Lisa; Short, Susan; Lawler, Sean E.

doi:10.1016/j.molonc.2014.11.004

Cited by 57 publications

(30 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, they identified a specific miRNA gene signature that correlated with patient clinical outcomes for all 5 glioblastoma sub-groups. Finally, a very recent report used LASSO regression models to identify a 9-miRNA prognostic signature that significantly correlated with survival in all glioblastoma subtypes except the non-G-CIMP pro-neural group (81). Collectively, these reports suggest that stratifying each individual patient based on their differential miRNA expression signatures may result in personalized sub-class specific treatment strategies in the future.…”

Section: Predicting Glioblastoma Patient Outcome By Differential Mirnmentioning

confidence: 98%

MicroRNA as potential biomarkers in Glioblastoma

et al. 2015

View full text Add to dashboard Cite

Glioblastoma is the most aggressive and lethal tumour of the central nervous system and as such the identification of reliable prognostic and predictive biomarkers for patient survival and tumour recurrence is paramount. MicroRNA detection has rapidly emerged as potential biomarkers, in patients with glioblastoma. Over the last decade, analysis of miRNA in laboratory based studies have yielded several candidates as potential biomarkers however, the accepted use of these candidates in the clinic is yet to be validated. Here we will examine the use of miRNA signatures to improve glioblastoma stratification into subgroups and summarise recent advances made in miRNA examination as potential biomarkers for glioblastoma progression and recurrence.

show abstract

Section: Predicting Glioblastoma Patient Outcome By Differential Mirnmentioning

confidence: 98%

MicroRNA as potential biomarkers in Glioblastoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Meanwhile, miRNA expression profiling has been shown to distinguish the diagnosis and tumor stage of cancers more accurately than traditional mRNA analysis (64). Hundreds of studies have sought to identify miRNA serum signatures/profiles for different pathological conditions (mostly cancers); such studies have used miRNA panels to detect breast cancer (65), identify metastatic prostate cancer (66), diagnose and predict recurrence for bladder cancer (67), stratify and predict risk in glioblastoma patients (68), detect colorectal cancer (69, 70), discriminate the metastatic subtype of colorectal cancer (71), predict the prognosis and distant metastasis of colorectal cancer (72), perform early detection of pancreatic cancer (73), accurately distinguish malignant cutaneous T-cell lymphoma from benign inflammatory skin disorders (psoriasis, atopic dermatitis, contact dermatitis) (74), and association to lupus nephritis (75). Indeed, Brand et al recently showed that the use of a five-miRNA panel plus cytology improved preoperative pancreatic cancer diagnosis, correctly identifying pancreatic cancer in 91% of positive samples, compared to the 79% sensitivity seen for cytology alone.…”

Section: Ii- Biomarker Signaturesmentioning

confidence: 99%

Biomarkers of Inflammatory Bowel Disease

Viennois

Zhao

Merlin

2015

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and severity assessment and therapeutic outcomes. Laboratory biomarkers can be used in the diagnosis and management of IBD but none of them has been proven to be ideal. Increasing efforts are being made to discover new biomarkers that can discriminate between the types of IBD, predict future responses to treatment, and aid in differential diagnosis, treatment planning and prognosis prediction. This review addresses the potential for current biomarkers and the emergence of the concept of biomarker signatures in IBD diagnostic and personalized medicine.

show abstract

“…Some microRNAs have been linked to a specific GBM subtype such as the expression of miR-18 family and miR-218 which are significantly downregulated in mesenchymal subtype, whereas miR-34a has been shown to be preferentially expressed in proneural subset [19-21]. A group of nine microRNAs associated with pathobiology and therapeutic responsiveness of GBM, have been recently shown as a cluster of prognostic biomarkers [22]. Based on TCGA microRNA dataset, miR-128 can also classify more aggressive mesenchymal phenotype as its expression is significantly down regulated in this subtype compared to proneural [23].…”

Section: Micrornas and Gbm Subtypesmentioning

confidence: 99%

MicroRNA and extracellular vesicles in glioblastoma: small but powerful

2016

View full text Add to dashboard Cite

To promote the tumor growth, angiogenesis, metabolism, and invasion, glioblastoma multiforme (GBM) cells subvert the surrounding microenvironment by influencing the endogenous activity of other brain cells including endothelial cells, macrophages, astrocytes, and microglia. Large number of studies indicates that the intracellular communication between the different cell types of the GBM microenvironment occurs through the functional transfer of oncogenic components such as proteins, non-coding RNAs, DNA and lipids via the release and uptake of extracellular vesicles (EVs). Unlike the communication through the secretion of chemokines and cytokines, the transfer and gene silencing activity of microRNAs through EVs is more complex as the biogenesis and proper packaging of microRNAs is crucial for their uptake by recipient cells. Although the specific mechanism of EV-derived microRNA uptake and processing in recipient cells is largely unknown, the screening, identifying and finally targeting of the EV-associated pro-tumorigenic microRNAs are emerging as new therapeutic strategy to combat the GBM.

show abstract

Prediction of clinical outcome in glioblastoma using a biologically relevant nine‐microRNA signature

Cited by 57 publications

References 51 publications

MicroRNA as potential biomarkers in Glioblastoma

MicroRNA as potential biomarkers in Glioblastoma

Biomarkers of Inflammatory Bowel Disease

MicroRNA and extracellular vesicles in glioblastoma: small but powerful

Contact Info

Product

Resources

About